Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels
Open Access
- 25 August 2022
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (3) , 196-203
Abstract
Objective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR::ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCRABL1 International Scale (IS). We aimed to investigate the prognostic role of BeR:ABL1 transcript levels, HT, and RR on molecular response kinetics at 3 months in patients with newly diagnosed chronic-phase (CP)-CML. Materials and Methods: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. BCR::ABL1 transcript levels and molecular responses at baseline and at 3, 6, 12, and 24 months of treatment were evaluated retrospectively. Major molecular response (MMR) at 12 months and event-free survival (EFS) were determined as primary endpoints and the effects of treatment kinetics on these parameters were examined. Results: Of the 40 patients, BCR:ABL1 IS was <= 10% at 3 months in 72.5%, representing EMR. The rate of event occurrence was 45.50/u in patients with BCR:ABL1 IS of >10%, whereas it was 6.9% in those with BCRABL1 IS of 10% (p=0.004). MMR was detected in 62.1% of the patients with EMR and in 9.1% of those without EMR (p=0.003). The cut-off value for achieving MMR was 24 days for HT and 0.04 for RR. Deep molecular response (DMR) at 24 months was associated with HT of 24 days and RR of 0.04. EFS was found to be significantly better in the group with BCRABL1 IS of 100/c) and HT of 24 days (p=0.001) and in the group with BCRABL1 IS of <= 10% and RR of < 0.04 (p=0.007) compared to others. Conclusion: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of 24 days and RR of <= 0.04 were more important than BCR::ABL1 IS of <= 10% in achieving DMR at 24 months, and the combination of BCRABL1 IS of <= 10% with both HI of <= 24 days and RR of <= 0.04 has the best predictive value for EFS.Keywords
This publication has 25 references indexed in Scilit:
- Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibLeukemia, 2014
- Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibBlood, 2014
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable DiseaseJournal of Clinical Oncology, 2014
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Blood, 2014
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBlood, 2013
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Leukemia, 2012
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Blood, 2012
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase InhibitorsJournal of Clinical Oncology, 2012
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010